Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

U.S. Patent Application 20190241896 for Modulators Of Dnm2 Expression

Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

Shuling GUO, Director, Doctor of Philosophy, Ionis Pharmaceuticals, Carlsbad, Antisense Drug Discovery

EP0517796B1 - Oligonucleotide analogs - Google Patents

JCI Insight - Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin

PDF) Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy

SLIM IMS-MS for Characterization of Antibody Drug Conjugates (ADCs)

IJMS, Free Full-Text

EP0348458B1 - Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes

A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect

SEC Filing Sarepta Therapeutics, Inc.